doxorubicin hydrochloride has been researched along with fosbretabulin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azhar, MA; Bharathi, EV; Dastagiri, D; Juvekar, A; Kamal, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, JS; Sen, S; Sultana, F; Zingde, S | 1 |
| Bhadra, MP; Bharathi, EV; Dastagiri, D; Kamal, A; Pushpavalli, SN; Ramaiah, MJ; Reddy, JS; Reddy, MK; Reddy, TL; Shaik, TB; Viswanath, A | 1 |
| Bedi, PM; Budhiraja, A; Gupta, MK; Kaur, C; Nepali, K; Saxena, AK; Sharma, S | 1 |
| Barkume, M; Chandra Shekar, K; Jadhav, S; Juvekar, A; Kamal, A; Khan, I; Kode, J; Kumar, CG; Kumar, GB; Pal-Bhadra, M; Patel, N; Rao, GK; Reddy, VS; Routhu, SR; Shaik, AB; Veena, I | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
| Ai, W; Bao, N; Chen, H; Li, S; Li, W; Wang, S | 1 |
| Bi, Y; Li, W; Ma, C; Shuai, W; Sun, H; Xu, F; Xu, J; Xu, S; Yao, H; Zhu, Z | 1 |
| Chen, ZS; Li, W; Liu, Y; Shuai, W; Tan, Y; Xu, J; Xu, S; Yang, DH; Yang, L; Yao, H; Zheng, T; Zhu, H; Zhu, Z | 1 |
| Han, L; Huang, X; Jin, X; Li, X; Liang, B; Ouyang, F; Xu, Y; Yan, J; Zhan, M; Zhang, Q | 1 |
| Chen, C; Deng, Y; He, L; Hu, M; Li, B; Li, H; Yin, H; Zhang, J | 1 |
10 other study(ies) available for doxorubicin hydrochloride and fosbretabulin
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Benzodiazepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Design; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Isoxazoles | 2010 |
Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Molecular Structure; Quinazolinones; Stereoisomerism | 2011 |
Chalcone based azacarboline analogues as novel antitubulin agents: design, synthesis, biological evaluation and molecular modelling studies.
Topics: Antineoplastic Agents; Carbolines; Cell Line, Tumor; Chalcone; Chemistry Techniques, Synthetic; Drug Design; Humans; Models, Molecular; Molecular Conformation; Structure-Activity Relationship; Tubulin Modulators | 2014 |
Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Chalcones; Dose-Response Relationship, Drug; Drug Design; Female; Humans; MCF-7 Cells; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2017 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
The inhibitory effect of kokusaginine on the growth of human breast cancer cells and MDR-resistant cells is mediated by the inhibition of tubulin assembly.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dictamnus; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Furans; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Tubulin | 2018 |
Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Colchicine; Drug Design; Drug Screening Assays, Antitumor; Heterografts; Humans; Indoles; K562 Cells; Neoplasms; Quinolines; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2019 |
Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Neoplasms; Neovascularization, Physiologic; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2021 |
Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Thioredoxin-Disulfide Reductase; Tubulin; Tubulin Modulators | 2022 |
Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Leukemia; Molecular Structure; Structure-Activity Relationship | 2022 |